Early ADT for Recurrent Prostate Cancer Challenged
Men with biochemically recurrent nonmetastatic prostate cancer following radical prostatectomy have long survival times from the time of surgery without hormonal treatment, a study found.
PROSTATE CANCER ADVISOR
Prostate Cancer
Features
-
-
Data May Support Routine Tumor Testing for HRR Gene Alterations in mCRPC
Almost 28% of men with metastatic castration-resistant prostate cancer harbor alterations in homologous recombination repair genes, a study found. -
Sipuleucel-T Efficacy, Safety in mCRPC Evaluated in Real World Study
The median time from first infusion of sipuleucel-T to death from prostate cancer was 42.7 months. -
Men With High-Risk PCa and Low PSA May Benefit More From Surgery Than Radiation
In a study, radical prostatectomy for men with Gleason 8-10 prostate cancer and low PSA levels was associated with a lower death risk compared with external beam radiation therapy with or without brachytherapy. -
Prospective Study Characterizes PCa Risk Linked to BRCA1, BRCA2 Mutations
For decades, it has been known that the mutations in the tumor suppressor genes BRCA1 and BRCA2 are associated with high risks of breast and ovarian cancer, but a new prospective cohort study provides the strongest evidence to date that these mutations are associated with the development of prostate cancer (PCa). The BRCA2 mutation appears… -
Skeletal-Related Events Common After CRPC Development
Large observational study reveals a 40% cumulative incidence rate of first skeletal-related events following development of castration-resistant prostate cancer.
Latest Prostate Cancer News
Optimal Drug Sequencing for mCRPC Reported
For men with newly diagnosed metastatic castration-resistant prostate cancer, starting with abiraterone plus prednisone followed by enzalutamide upon PSA progression significantly prolongs time to second PSA progression compared with the opposite sequence, a study found.
Current Statin Use May Lower Risk for Lethal Prostate Cancer
Strong inverse association found for PTEN-null cancer but not for PTEN-intact cancers
Screening of Prostate Cancer Patients for BRCA1/2 “Remains Unclear”
Even though the EMBRACE study adds to the literature, according to authors the “best way” to screen men with germline DNA damage repair abnormalities “remains unclear.”
Dietary Patterns May Possibly Be Linked to Prostate Cancer Risk
Plant-based diets might lower risk, animal-based diets containing dairy might raise risk for prostate cancer
Psychosocial Concerns Common After Prostate Cancer Treatment
Depression and anxiety about cancer recurrence are among the issues that face many men following treatment for prostate cancer.
More Appropriate Prostate Cancer Tx Seen at Multidisciplinary Clinic
Patients with low-risk disease more likely to receive nondefinitive therapy at MultiD clinic versus SEER.
PSA Levels No Different With Exposure to Antidiabetes Meds
Regardless of PSA levels triggering biopsy, no difference in prostate cancer detection at biopsy.
Pathogenic, Likely Pathogenic Variants Common in Prostate Cancer
Variety of ethnicities need to be included in studies of germline testing to better understand variants.
Prostate Cancer Active Surveillance Appropriate for Blacks
Active surveillance (AS) is an appropriate management strategy for black men with favorable-risk prostate cancer (PCa) who adhere to a standardized protocol of regular PSA tests and biopsies, investigators reported. The prospective, multi-institutional cohort Canary Prostate Cancer Active Surveillance Study (PASS), which included 1315 men on AS, found that black men were at no higher…
Investigating the Role of Salvage Lymph Node Dissection in Nonmetastatic CRPC
Traditionally, approaches to the management of patients with nonmetastatic CRPC following radical prostatectomy have been limited.
Want to read more?
Please login or register first to view this content.
Next post in Prostate Cancer
